8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is open-label, randomized, multicentre study to compare the efficacy and safety of the
8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C
patients.
All the recruited subjects will receive the treatment accordingly and be followed up for 24
weeks following the completion of treatment.